SUBSCRIBE
SUBSCRIBE

Immunic Therapeutics

IN THE PRESS
Pharm Country
Immunic to Host MS R&D Day and Participate in Investor Conferences in April 2024
April 4, 2024
 · 
5 min read
Pharm Country
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
March 20, 2024
 · 
8 min read
Pharm Country
Immunic to Participate in Investor and Scientific Conferences in March 2024
March 7, 2024
 · 
6 min read
Pharm Country
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 15, 2024
 · 
5 min read
Pharm Country
Immunic to Participate in Investor and Scientific Conferences in February
February 1, 2024
 · 
5 min read
Pharm Country
Immunic, Inc. Announces Private Placement of up to $240 Million
January 5, 2024
 · 
8 min read
Pharm Country
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
January 5, 2024
 · 
12 min read
Pharm Country
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis
November 21, 2023
 · 
8 min read
Business
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023
 · 
17 min read
Business
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
November 7, 2023
 · 
5 min read
Load More
JOBS